Sugi Predict

Sugi Predict / Compounds / SCHEMBL3005286

SCHEMBL3005286

SCHEMBL3005286

COC(=O)c1ccc(CCNC(=O)C(F)(F)F)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 1/20 0.56
▸ CYP4A11 Q02928 2/20 0.54
▸ CYP4F2 P78329 1/20 0.53
▸ LMNA P02545 3/20 0.52
▸ MAPT P10636 2/20 0.52
▸ LOXL2 Q9Y4K0 1/20 0.50
▸ MLYCD O95822 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ ALOX12 P18054 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ CKS1B P61024 1/20 0.46
▸ SKP2 Q13309 1/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12487022 0.91 CYP4A11 (0.59) MGLLCYP4A11CYP4F2MAPTLOXL2
SCHEMBL4465354 0.88 CYP4A11 (0.55) MGLLCYP4A11CYP4F2MAPTLOXL2
SCHEMBL8072288 0.84 LOXL2 (0.53) CYP4A11CYP4F2LMNAMAPTLOXL2
SCHEMBL6388384 0.84 ALDH1A1 (0.53) LMNAMAPTMLYCDALDH1A1HSD17B10
SCHEMBL140038 0.83 SMN1; SMN2 (0.67) ALDH1A1SMN1; SMN2MTNR1AMTNR1B
SCHEMBL3196978 0.83 MLYCD (0.54) LMNAMLYCDALDH1A1SMN1; SMN2POLB
SCHEMBL10887210 0.82 MLYCD (0.47) LMNAMLYCDALDH1A1HPGDSMN1; SMN2
SCHEMBL14966449 0.81 SMN1; SMN2 (0.68) MGLLCYP4A11CYP4F2LMNAMAPT
SCHEMBL14141265 0.81 NPC1 (0.59) MAPTALDH1A1TP53HPGDSMN1; SMN2
SCHEMBL3833704 0.81 MLYCD (0.46) LMNAMLYCDALDH1A1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195462-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2025-06-19 — — US disclosed
US-20240366552-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2024-11-07 — — US disclosed
US-20240115543-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2024-04-11 — — US disclosed
US-20230255923-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2023-08-17 — — US disclosed
WO-2022128850-A1 NOVEL ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2022-06-23 — — WO disclosed
US-20220142963-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2022-05-12 — — US disclosed
CN-108602811-B FXR receptor agonists 轩竹生物科技有限公司 2021-11-16 — — CN disclosed
US-20210315855-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2021-10-14 — — US disclosed
US-20210059972-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2021-03-04 — — US disclosed
US-20200230097-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC (CA) 2020-07-23 — — US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 — — US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 — — US disclosed
US-20100190852-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC. (CA) 2010-07-29 — — US disclosed
EP-2170050-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF Milestone Pharmaceuticals Inc. (CA) 2010-04-07 — — EP disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 — — US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 — — US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 — — US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 — — US disclosed
WO-2008156820-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF MILESTONE PHARMACEUTICALS INC. (CA) 2008-12-24 — — WO disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200230097-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 MGLL 1784/4885CYP4A11 2712/4885CYP4F2 3383/4885
US-20240115543-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 MGLL 1784/4885CYP4A11 2712/4885CYP4F2 3383/4885
US-20220142963-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 MGLL 1784/4885CYP4A11 2712/4885CYP4F2 3383/4885
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 MGLL 1383/4885CYP4A11 1793/4885CYP4F2 2810/4885
US-20230255923-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 MGLL 1784/4885CYP4A11 2712/4885CYP4F2 3383/4885
US-20240366552-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 MGLL 1784/4885CYP4A11 2712/4885CYP4F2 3383/4885
US-20210315855-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 MGLL 1784/4885CYP4A11 2712/4885CYP4F2 3383/4885
US-20210059972-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 MGLL 1784/4885CYP4A11 2712/4885CYP4F2 3383/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MGLL 1383/4885CYP4A11 1793/4885CYP4F2 2810/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MGLL 1383/4885CYP4A11 1793/4885CYP4F2 2810/4885
US-20100190852-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 MGLL 1784/4885CYP4A11 2712/4885CYP4F2 3383/4885
US-20250195462-A1 SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF ORAI1, ATP2A1, RYR2 MGLL 1784/4885CYP4A11 2712/4885CYP4F2 3383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.